257 related articles for article (PubMed ID: 2703278)
1. Effect of cyclophosphamide and levan treatment on bone marrow and peripheral blood cells in B16-F10 melanoma-bearing mice.
Leibovici J; Siegal A; Kopel S; Davidai G; Yavetz H
Int J Immunopharmacol; 1989; 11(2):133-47. PubMed ID: 2703278
[TBL] [Abstract][Full Text] [Related]
2. Effect of tumor inhibitory and stimulatory doses of levan, alone and in combination with cyclophosphamide, on spleen and lymph nodes.
Leibovici J; Kopel S; Siegal A; Gal-Mor O
Int J Immunopharmacol; 1986; 8(4):391-403. PubMed ID: 3744640
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow and peripheral blood modifications in C57BL mice administered with cyclophosphamide and levan.
Siegal A; Kopel S; Bar-Sela S; Davidai G; Yavetz H; Leibovici J
In Vivo; 1988; 2(5):349-59. PubMed ID: 2979857
[TBL] [Abstract][Full Text] [Related]
4. Opposite effects on tumor growth depending on dose of an immunomodulatory polysaccharide with or without cyclophosphamide.
Leibovici J; Kopel S; Wolman M
Anticancer Res; 1985; 5(5):553-8. PubMed ID: 4062258
[TBL] [Abstract][Full Text] [Related]
5. Histological changes in spleen and lymph nodes of mice administered cyclophosphamide and levan.
Siegal A; Kopel S; Leibovici J
Cell Tissue Res; 1986; 245(1):183-8. PubMed ID: 3488127
[TBL] [Abstract][Full Text] [Related]
6. Effect of administration schedule on the levan-cyclophosphamide combined treatment of Lewis lung carcinoma.
Stark Y; Leibovici J; Wolman M
Int J Immunopharmacol; 1983; 5(4):289-97. PubMed ID: 6629589
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells.
Palomares T; Alonso-Varona A; Alvarez A; Castro B; Calle Y; Bilbao P
Clin Exp Metastasis; 1997 May; 15(3):329-37. PubMed ID: 9174132
[TBL] [Abstract][Full Text] [Related]
8. Combined effect of levan and cytotoxic agents on the growth of experimental tumours in mice.
Leibovici J; Stark Y; Wolman M
Br J Exp Pathol; 1983 Jun; 64(3):239-44. PubMed ID: 6882675
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen in trimodal therapy with cytotoxic drugs and hyperthermia in vivo significantly enhance therapeutic efficacy against B16-F10 melanoma.
Misir Krpan A; Ivankovic S; Krajina Z; Ivankovic D; Stojkovic R
Tumori; 2012; 98(2):257-63. PubMed ID: 22677994
[TBL] [Abstract][Full Text] [Related]
10. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory and stimulatory effects of levan on growth of B16 melanoma--possible mechanisms.
Yavetz H; Davidai G; Leibovici J; Wolman M
Cell Mol Biol; 1985; 31(5):343-7. PubMed ID: 4084939
[No Abstract] [Full Text] [Related]
12. Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide.
Cichoń T; Jarosz M; Smolarczyk R; Ogórek B; Matuszczak S; Wagner M; Mitrus I; Sochanik A; Jazowiecka-Rakus J; Szala S
Acta Biochim Pol; 2012; 59(3):377-81. PubMed ID: 22946026
[TBL] [Abstract][Full Text] [Related]
13. Morphology of the bone marrow, spleen and liver during hematopoietic cell mobilization with cyclophosphamide in mice.
Barcew K; Karbicka A; Szumilas P; Marchlewicz M; Grzegrzółka R; Wiszniewska B; Machaliński B
Folia Histochem Cytobiol; 2008; 46(4):501-9. PubMed ID: 19141405
[TBL] [Abstract][Full Text] [Related]
14. Further observations on the effect of cyclophosphamide on intratumor and peripheral leukocyte levels.
Evans R
Am J Pathol; 1980 Jun; 99(3):667-84. PubMed ID: 7386598
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.
Nikcevich DA; Duffie GP; Young MR; Ellis NK; Kaufman GE; Wepsic HT
Cell Immunol; 1987 Oct; 109(2):349-59. PubMed ID: 2959374
[TBL] [Abstract][Full Text] [Related]
17. Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells enhances the recruitment of CD11b(+) myeloid cells to the lungs and facilitates B16-F10 melanoma colonization.
Souza LE; Almeida DC; Yaochite JN; Covas DT; Fontes AM
Exp Cell Res; 2016 Jul; 345(2):141-9. PubMed ID: 26027946
[TBL] [Abstract][Full Text] [Related]
18. Combined interleukin 1 beta/interleukin 2 treatment in mice: synergistic myelostimulatory activity and protection against cyclophosphamide-induced myelosuppression.
Proietti E; Tritarelli E; Gabriele L; Testa U; Greco G; Pelosi E; Gabbianelli M; Belardelli F; Peschle C
Cancer Res; 1993 Feb; 53(3):569-76. PubMed ID: 8425189
[TBL] [Abstract][Full Text] [Related]
19. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
20. In vivo modulation of myelopoiesis and immune functions by maleic anhydride divinyl ether copolymer (MVE-2) in tumor-free and MBL-2 tumor-bearing mice treated with cyclophosphamide.
Schlick E; Ruffmann R; Chirigos MA; Welker RD; Herberman RB
Cancer Res; 1985 Mar; 45(3):1108-14. PubMed ID: 3871661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
